百济神州在肺癌试验失败后放弃TIGIT抗体BeiGene abandons TIGIT antibody after lung cancer flop

动脉网
03 Apr

BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.百济神州决定停止开发其靶向TIGIT的药物ociperlimab,这是该药物类别遭遇的又一次挫折。The Nasdaq-listed company...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10